Report cover image

Germany Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Jun 18, 2025
Length 150 Pages
SKU # GV20191976

Description

Germany Pharmaceuticals Market Growth & Trends

The Germany pharmaceuticals market size is estimated to reach USD 151.51 billion by 2033, registering to grow at a CAGR of 5.31% from 2025 to 2033 according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.

Furthermore, rising clinical trials and approval of novel immune-suppressive therapies are anticipated to propel market growth. For instance, in June 2020, Sandoz International GmbH launched Dailiport capsules (generic tacrolimus) in Germany and other European countries. Dailiport capsules are indicated for adult kidney and liver transplant patients.

In addition, the export of pharmaceutical products by pharmaceutical companies in Germany to various countries is expected to fuel market growth. For instance, according to Germany Trade and Invest, in China, 22.0% of imported pharmaceutical products are from German companies.

Key players entering into strategic initiatives such as partnership, licensing, acquisition, and collaboration to expand and strengthen their regional presence is expected to boost the market growth. For instance, in November 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. This acquisition was aimed at helping the company expand its oncology portfolio worldwide and develop innovative medicines.

In addition, rising funds by organizations for the development of pipeline drugs are anticipated to accelerate market growth. For instance, in January 2019, Atriva Therapeutics GmbH closed its series A financing led by Meneldor and High-Tech Gründerfonds GmbH (HTGF) for its lead drug candidate ATR-002. This drug candidate is developed against influenza infection and other respiratory infections.

Various other organizations, such as the European Cancer Organisation (ECCO), European Cancer Patient Coalition (ECPC), and European Organisation for Research and Treatment of Cancer (EORTC) provide funds for cancer research programs and treatment plans.

Furthermore, increasing the availability of generic drugs at a lower price is expected to boost the market growth. For instance, in July 2019, Sandoz of Novartis AG launched a generic version of gefitinib for locally advanced or metastatic NSCLC. The launch of the generic version is estimated to increase the number of patients treated due to the favorable cost of the drug.

Germany Pharmaceuticals Market Report Highlights
  • Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
  • The branded segment dominated the Germany pharmaceutical industry with a revenue share of 66.86% in 2024
  • The prescription segment dominated the market with a revenue share of 86.76% in 2024.
  • The cancer segment dominated the market with a revenue share of 18.06% in 2024.
  • The oral segment dominated the market with a revenue share of 57.53% in 2024.
  • The adult segment dominated the market with a revenue share of 62.84% in 2024
  • The hospital pharmacy segment dominated the market with a revenue share of 53.53% in 2024
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Germany Pharmaceutical Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Advancement in therapeutics and robust product pipeline
3.3.1.2. Rise in pharmaceutical r&d spending
3.3.1.3. Rise in pharmaceutical r&d spending
3.3.2. Market Restraints Analysis
3.3.2.1. Patent expiration of key market drugs
3.3.2.2. Pricing pressures on bio/pharmaceutical companies
3.3.2.3. Stringent regulatory scenario
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
Chapter 4. Germany Pharmaceutical Market: By Drug Estimates & Trend Analysis
4.1. Germany Pharmaceutical Market: Drug Segment Dashboard
4.2. Germany Pharmaceutical Market: By Drug Movement Analysis, 2024 & 2033 (USD Million)
4.3. Biologics & Biosimilars (Large Molecules)
4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2. Monoclonal Antibodies
4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.3. Vaccines
4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.4. Cell & Gene Therapy
4.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.5. Others
4.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Conventional Drugs (Small Molecules)
4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Germany Pharmaceutical Market: Type Estimates & Trend Analysis
5.1. Germany Pharmaceutical Market: Type Segment Dashboard
5.2. Germany Pharmaceutical Market: By Product Movement Analysis, 2024 & 2033 (USD Million)
5.3. Prescription
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. OTC
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Germany Pharmaceutical Market: Product Estimates & Trend Analysis
6.1. Germany Pharmaceutical Market: Product Segment Dashboard
6.2. Germany Pharmaceutical Market: By Product Movement Analysis, 2024 & 2033 (USD Million)
6.3. Branded
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Generics
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Germany Pharmaceutical Market: Disease Estimates & Trend Analysis
7.1. Germany Pharmaceutical Market: Disease Segment Dashboard
7.2. Germany Pharmaceutical Market: By Disease Movement Analysis, 2024 & 2033 (USD Million)
7.3. Cardiovascular diseases
7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Cancer
7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Diabetes
7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Infectious diseases
7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Neurological disorders
7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Respiratory diseases
7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9. Autoimmune diseases
7.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10. Mental health disorders
7.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11. Gastrointestinal disorders
7.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12. Women’s Health Diseases
7.12.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13. Genetic and Rare genetic diseases
7.13.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.14. Dermatological conditions
7.14.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.15. Obesity
7.15.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.16. Renal diseases
7.16.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.17. Liver conditions
7.17.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.18. Hematological disorders
7.18.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.19. Eye conditions
7.19.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.20. Infertility conditions
7.20.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.21. Endocrine disorders
7.21.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.22. Allergies
7.22.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.23. Others
7.23.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Germany Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
8.1. Germany Pharmaceutical Market: Route of Administration Segment Dashboard
8.2. Germany Pharmaceutical Market: By Route of Administration Movement Analysis, 2024 & 2033 (USD Million)
8.3. Oral
8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. Tablets
8.3.3. Capsules
8.3.4. Suspensions
8.3.5. Other
8.4. Topical
8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Parenteral
8.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. Intravenous
8.5.3. Intramuscular
8.6. Inhalations
8.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Other Routes of Administration
8.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Germany Pharmaceutical Market: Age Group Estimates & Trend Analysis
9.1. Germany Pharmaceutical Market: Age Group Segment Dashboard
9.2. Germany Pharmaceutical Market: By Age Group Movement Analysis, 2024 & 2033 (USD Million)
9.3. Children & Adolescents
9.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4. Adults
9.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Geriatric
9.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Germany Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis
10.1. Germany Pharmaceutical Market: Distribution Channel Segment Dashboard
10.2. Germany Pharmaceutical Market: By Distribution Channel Movement Analysis, 2024 & 2033 (USD Million)
10.3. Hospital Pharmacy
10.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4. Retail Pharmacy
10.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Others
10.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Recent Developments & Impact Analysis by Key Market Participants
11.2. Company Categorization
11.3. Participant Overview
11.4. Financial Performance
11.5. Product Bench Marking
11.6. Company Market Share Analysis, 2024
11.7. Company Profiles
11.7.1. Bayer AG
11.7.1.1. Participant’s Overview
11.7.1.2. Financial Performance
11.7.1.3. Product Benchmarking
11.7.1.4. Recent Developments/ Strategic Initiatives
11.7.2. Boehringer Ingelheim
11.7.2.1. Participant’s Overview
11.7.2.2. Financial Performance
11.7.2.3. Product Benchmarking
11.7.2.4. Recent Developments/ Strategic Initiatives
11.7.3. Merck KGaA
11.7.3.1. Participant’s Overview
11.7.3.2. Financial Performance
11.7.3.3. Product Benchmarking
11.7.3.4. Recent Developments/ Strategic Initiatives
11.7.4. AbbVie Inc.
11.7.4.1. Participant’s Overview
11.7.4.2. Financial Performance
11.7.4.3. Product Benchmarking
11.7.4.4. Recent Developments/ Strategic Initiatives
11.7.5. Evotec SE
11.7.5.1. Participant’s Overview
11.7.5.2. Financial Performance
11.7.5.3. Product Benchmarking
11.7.5.4. Recent Developments/ Strategic Initiatives
11.7.6. Dermapharm Holding SE
11.7.6.1. Participant’s Overview
11.7.6.2. Financial Performance
11.7.6.3. Product Benchmarking
11.7.6.4. Recent Developments/ Strategic Initiatives
11.7.7. BioNTech SE
11.7.7.1. Participant’s Overview
11.7.7.2. Financial Performance
11.7.7.3. Product Benchmarking
11.7.7.4. Recent Developments/ Strategic Initiatives
11.7.8. Sanofi
11.7.8.1. Participant’s Overview
11.7.8.2. Financial Performance
11.7.8.3. Product Benchmarking
11.7.8.4. Recent Developments/ Strategic Initiatives
11.7.9. Biotest AG
11.7.9.1. Participant’s Overview
11.7.9.2. Financial Performance
11.7.9.3. Product Benchmarking
11.7.9.4. Recent Developments/ Strategic Initiatives
11.7.10. F. Hoffmann-La Roche Ltd
11.7.10.1. Participant’s Overview
11.7.10.2. Financial Performance
11.7.10.3. Product Benchmarking
11.7.10.4. Recent Developments/ Strategic Initiatives
Chapter 12. Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us